A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
Caldera starts up with $112.5M and a dual-targeting immune drug from China
Caldera starts up with $112.5M and a dual-targeting immune drug from China
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target
Digital health funding increases in 2025, spurred by AI: report
Digital health funding increases in 2025, spurred by AI: report
What Sanofi’s multiple sclerosis troubles could mean for the space
What Sanofi’s multiple sclerosis troubles could mean for the space
AbbVie pledges $100B to US production in drug pricing deal with Trump
AbbVie pledges $100B to US production in drug pricing deal with Trump
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
5 questions facing biopharma in 2026
5 questions facing biopharma in 2026
Building more sustainable cold chain packaging through innovation
Building more sustainable cold chain packaging through innovation
Best practices for COA selection: Building a stronger foundation for clinical trials
Best practices for COA selection: Building a stronger foundation for clinical trials
Eikon, a high-profile startup led by Merck vets, seeks an IPO
Eikon, a high-profile startup led by Merck vets, seeks an IPO
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
Aktis raises $318M in 2026’s first biotech IPO
Aktis raises $318M in 2026’s first biotech IPO
Alveus launches with $160M to advance MariTide-like obesity drug
Alveus launches with $160M to advance MariTide-like obesity drug
Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz
Parabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz
Diagonal banks another $125M for ‘clustering’ antibody drugs
Diagonal banks another $125M for ‘clustering’ antibody drugs
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page